Epirubicin belongs to Anthracycline, while both Trastuzumab and Pertuzumab belong to Her2-targeted therapies, all of which are known to damage cardiomyocyte leading to heart failure [15-16]. The gene discussed is ERBB2; the disease is heart failure.